Page 335 - fbkCardioDiabetes_2017
P. 335

Cardio Diabetes Medicine 2017                                    311







                                      International Lipid Guidelines :

                                        What is Needed for Indians ?




                                                     Dr. S. N. Narasingan,
                                            MD, FRCP [ Edin&Glasg] ,FACP,FICP,FCCP[USA]

                                  Former Adjunct Professor The Tamil Nadu Dr. MGR Medical University
                              Managing Director, SNN Specialities Clinic, & SNN Diagnostic Centre, Chennai





                 Abstract :                                         ] and newer updated guidelines from ACC/AHA are
                 There  are  number  of  guidelines  and recommenda-  highlighted in this chapter .
                 tions for  managing cholesterol  .American College
                 of Cardiology [ACC] / American Heart Association [   Introduction : Why do we need guidelines ?
                 AHA  ] guidelines  2013  focussed on Atherosclerotic   Many times we get conflicting  data  in guidelines.
                 Cardiovascular risk  and not  on lipid  goals  .  Interna-  What is reasonable to do for overall approach to make
                 tional Atherosclerosis Society [ IAS ] published global   sense of the totality of data ? What we should aspire
                 recommendations in the same year for the manage-   to do at a population level is to standardise care and
                 ment  of dyslipidemia  . National Lipid  Association   avoid inequalities. RCTs systematically test effects of
                 [NLA] guidelines were published in 2014 .Lipid Asso-  an intervention on pre-specified outcomes in defined
                 ciation of India [ LAI ]has released Expert Consensus   populations. Their use minimizes confounding . Their
                 Statement  on Management  of Dyslipidemia  in Indi-  ability to generalize results to real-world patients may
                 ans in  2016. European  Guidelines  on cardiovascular   be limited due to exclusion criteria . Observational /
                 disease prevention in clinical practice was published   Epidemiologic studies have world-wide in scope and
                 in 2016. .This chapter on Newer Lipid Guidelines : fo-  may assess ASCVD risk across populations .Cohort
                 cuses on interpretation of these international guide-  studies : evaluate mortality and morbidity within pop-
                 lines  including recommendations of LAI  which  may   ulations  .Guidelines are published based on robust
                 be applicable for Indians. Many aspects of lipid man-  evidence from RCTs , observational / epidemiological
                 agement targeting LDL- c and other lipoproteins are   &  cohort studies  .  Experimental  data are  taken into
                 discussed  in  detail  .Indians have typical  elevations   account.
                 of triglyceride  with low  levels  of HDL-c  and almost   Atherosclerosis  is  a preventable disorder.  Of all the
                 normal LDL- c levels. Atherogenic dyslipidemia which   lipoproteins, it is the LDL Cholesterol which plays a
                 is the characteristic  feature of Metabolic syndrome   central role  not only  in the initiation of atheroscle-
                 [MetS] and diabetes is characterised by an increase   rosis  but  also in the  progression  of atherosclerosis
                 in triglyceride levels with low HDL –c and increase in   ending in clinical cardiovascular events . Most robust
                 small dense LDL-c .In view of increasing prevalence   evidence for the role played by LDL –C comes from
                 of obesity , MetS and diabetes, there is  a need for   RCT’s  which  had used statins. The evidence clearly
                 different approach  in managing mixed dyslipidemia   shows that by reducing LDL –c, we get substantial re-
                 .Randomised Control Trials [ RCTs] focussing on lipid   duction in CV morbidity & mortality . Many secondary
                 lowering therapy have to be conducted for evidence   prevention trials , primary prevention trials, and trials
                 and to develop guidelines for Indian patients . Patient   conducted in high risk groups, clearly demonstrated
                 centric approach with evidence obtained from  epi-  the important role  of LDL-C reduction and the po-
                 demiological / observational data on the prevalence   tency of  statins  in reducing  the atherosclerotic  car-
                 and  type of dyslipidemia  were  given importance  in   diovascular risk .
                 the  recommendations  of LAI  which  are highlighted
                 in this chapter. Recently published guidelines in 2017   NCEP ATP III Guidelines : Many guidelines were pub-
                 are  AACE [ American Association of Clinical Endo-  lished by various academic bodies across the globe
                 crinologists] ADA [ American Diabetes Association   .After the publication of National Cholesterol Educa-


                                                    Cardio Diabetes Medicine
   330   331   332   333   334   335   336   337   338   339   340